As a pediatric kidney specialist, I treat children and adolescents in all areas of pediatric nephrology. These include general nephrology, acute kidney injury (AKI), dialysis, transplantation and tuberous sclerosis. I also consult on fetal care if there is a problem with the unborn baby’s kidneys.
I was drawn to the field of nephrology by the opportunity it presents to improve the outcomes for children with kidney problems. Working with children and their families, I help patients reach their full potential. Nephrology also allows me to practice across the entire spectrum of pediatric illness, from acute critical care, to chronic care and outpatient care.
My research is focused on short- and long-term outcomes for children who have AKI and those who are at risk for AKI. I’m interested in AKI epidemiology and outcomes, acute renal replacement therapy and investigation of novel urinary AKI biomarkers in the pediatric population.
In 2012, I established Prospective Pediatric AKI Research Group (ppAKI-RG). The ppAKI-RG is comprised of more than 60 centers around the world with the goal of improving outcomes for the child with, or at-risk for, AKI. This consortium focuses on multicentered research studies that are dedicated to understanding and treating AKI in pediatric patients. This group has completed three major, unprecedented national and international studies to accurately characterize pediatric AKI epidemiology, reduce AKI and improve patient outcomes.
I also developed the only pediatric-specific, acute-care nephrology subspecialty fellowship with graduates who are now leaders in the field of pediatric AKI.
MD: Columbia College of Physicians and Surgeons, New York, NY, 1990.
Residency: Baylor College of Medicine, Houston, TX.
Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA.
Acute kidney injury; continuous renal replacement therapy; cardio-renal syndrome; nephrotoxic medication associated morbidity
Nephrology and Hypertension, Dialysis, End-Stage Renal Disease, Tuberous Sclerosis, Nephrology - Acute Care, Heart, Colorectal Disorders, Fontan Management
Acute kidney injury epidemiology and biomarkers; heart failure associated chronic kidney disease; nephrotoxic medication associated acute kidney injury reduction
Cardiology, Nephrology and Hypertension, Heart
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Serum renin and prorenin concentrations predict severe persistent acute kidney injury and mortality in pediatric septic shock. Pediatric Nephrology. 2023; 38:3099-3108.
Acute kidney injury biomarker olfactomedin 4 predicts furosemide responsiveness. Pediatric Nephrology. 2023; 38:3153-3161.
Long-Term Healthcare Cost Savings of a Pediatric Nephrotoxic Medication-Associated Acute Kidney Injury Reduction Program in a Simulated Sample. Journal of Pharmacy Practice. 2023; 36:795-802.
Overcoming Barriers to Drug Development in Children with CKD. Clinical journal of the American Society of Nephrology : CJASN. 2023; 18:1101-1107.
Neonatal nephrotoxic medication exposure and early acute kidney injury: results from the AWAKEN study. Journal of Perinatology. 2023; 43:1029-1037.
Premature infants born <28 weeks with acute kidney injury have increased bronchopulmonary dysplasia rates. Pediatric Research. 2023; 94:676-682.
Associations Between Characteristics of Individuals With Fontan Circulation With Blood and Urine Biomarkers of Kidney Injury and Dysfunction. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2023; 12:e029130.
Acute kidney injury and early fluid load in a retrospective cohort of neonatal sepsis. Pediatric Nephrology. 2023; 38:1971-1977.
Stuart L. Goldstein, MD, FAAP, FNKF, Prasad Devarajan, MD12/7/2023
Stuart L. Goldstein, MD, FAAP, FNKF4/5/2022
Stuart L. Goldstein, MD, FAAP, FNKF6/30/2019